The registered capital of the company is 35 million US dollars and it is a wholly-owned subsidiary of Aurobindo Pharma Ltd. in India. Alabindo Pharmaceutical Company is the second largest pharmaceutical listed company in India and is a large multinational corporation with factories or offices in China, the United States, Europe, South America, and South Africa.
Company Profile
With a registered capital of 35 million US dollars, Aurovitas is a wholly-owned subsidiary of Aurobindo Pharma Ltd. in India.
Aurobindo Pharma is the second largest listed pharmaceutical company in India, which is a large multinational company with factories or offices in China, the United States, Europe, South America and South Africa. The headquarter has a total of 350 approved US generic drugs, which is more than the sum of drugs by all China pharmaceutical companies approved in the United States. It ranks first in the global sales of APIs and among the top of the pharmaceutical companies. The Headquarter, owning the world's leading R&D center, has more than 20,000 employees all over the world, which developed more than 150 markets with annual sales of more than 26 billion US dollars.
The total investment of Aurovitas Pharma Taizhou is 100 million US dollars. This plant covers an area of approximately 97 mu, with a total construction area of 81,700 square meters. The proposed formulation includes tablet and hard capsule with an annual production capacity of 10 billion tablets and 5.5 billion capsules.
350个
generic drugs approved
20000+
20000 employees in Headquarters
150+
150 markets developed
260亿
More than 26 billion US dollars for annual sales
- Passed EU GMP Inspection in June.
- PQ completion of large-scale commercial batch equipment and facilities
- Completion of PQ for small commercial batch equipment and facilities
- Complete 14 product technology transfers
- More than 50 imported product registrations have been completed, and 4 formulations and 2 active pharmaceutical ingredients have been approved
- QC laboratory enters GMP status
- Small commercial batch production area completed decoration
- Obtaining a Chinese drug production license
- Internal decoration of factory buildings and equipment procurement
- QC laboratory instruments enter the IOQ stage
- The first drug registration materials in January are officially submitted
- Top sealing of the quality inspection comprehensive building in October
- Top of the production workshop building in November
- On January 29th, Anruovita Pharmaceutical Taizhou Co., Ltd. was registered and established
- On July 20th, the self built factory building broke ground and started construction
- Expected to be approved by the US FDA at the beginning of the year
- Expected to obtain Chinese registered drug license by the end of the year
- Product sales
Corporate Culture
Make good use of talents
Employees are the most valuable asset of a company
Staff
Responsibility
Idea